Oropharynx Tumor Board: A Primer for the General Otolaryngologist
2016 AAO-HNSF Annual Meeting &OTO EXPOSM
Keyword(s)
oropharyngeal squamous cell cancer (OPSCC), transoral surgery, HPV, immunotherapy
Radiation or chemoradiation has been the mainstay of treatment for oropharyngeal squamous cell cancer (OPSCC). In recent years, the increased use of transoral surgery (including transoral robotic surgery and transoral laser surgery) has added complexity to decision making for these patients. This seminar will utilize a tumor board-style discussion to highlight current management algorithms for OPSCC patients, focusing on the decision to treat primarily with or without surgery. Designed for the general otolaryngologist, topics will include the optimal workup for OPSCC including approaches to the unknown primary, patient selection, the role of human papillomavirus (HPV) testing, and a multi-disciplinary review of surgical and non-surgical treatment options.
Description
Radiation or chemoradiation has been the mainstay of treatment for oropharyngeal squamous cell cancer (OPSCC). In recent years, the increased use of transoral surgery (including transoral robotic surgery and transoral laser surgery) has added complexity to decision making for these patients. This seminar will utilize a tumor board-style discussion to highlight current management algorithms for OPSCC patients, focusing on the decision to treat primarily with or without surgery. Designed for the general otolaryngologist, topics will include the optimal workup for OPSCC including approaches to the unknown primary, patient selection, the role of human papillomavirus (HPV) testing, and a multi-disciplinary review of surgical and non-surgical treatment options. Learning Objectives: 1: Discuss the pros and cons of surgical and non-surgical treatment options for oropharyngeal squamous cell carcinoma (OPSCC). 2: Describe a rational approach to of the workup and treatment of unknown primary OPSCC. 3: Understand ongoing trials in transoral surgery, including potential changes in therapy due to HPV and the emerging role of immunotherapy. Faculty: Tamer Ghanem, MD, PhD(No relationships to disclose); Daniel Clayburgh, MD, PhD(No relationships to disclose); Umamaheswar Duvvuri, MD, PhD(No relationships to disclose); Neil Gross, MD(Intuitive Surgical: Consultant/Advisory Board, travel support; Medrobotics: Consultant/Advisory Board, travel support); Julie E. Bauman, MD, MPH(Eli Lilly: Consultant/Advisory Board; Kolltan: Consultant/Advisory Board; Merck: Consultant/Advisory Board, Research Grant; Merck Serono: Consultant/Advisory Board); Clifton David Fuller, MD, PhD(GE Health Technologies/MD Anderson Center for Advanced Biomedical Imaging In-Kind Award: Research Grant; MD Anderson Center for Radiation Oncology Research: Research Grant; National Institutes of Health MD Anderson Cancer Center Paul Calabresi Clinical Oncology Award: Research Grant; National Institutes of Health/National Cancer Institute Grant: Research Grant; National Institutes of Health/National Institute of Dental and Craniofacial Research: Research Grant; Elekta AB/MD Anderson MRI-LinAc: Research Grant; Hope Foundation/Southwest Oncology Group: Research Grant; MD Anderson Institutional Research: Research Grant; National Institutes of Health/National Cancer Institute: Research Grant; National Science Foundation: Research Grant)
